Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.
Identifieur interne : 001464 ( Ncbi/Merge ); précédent : 001463; suivant : 001465Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.
Auteurs : Maria Gabriela Sánchez [Canada] ; Marc Morissette ; Thérèse Di PaoloSource :
- Progress in neuro-psychopharmacology & biological psychiatry [ 1878-4216 ] ; 2013.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (administration & dosage), Animals, Brain (diagnostic imaging), Brain (drug effects), Brain (metabolism), Citalopram, Estradiol (pharmacology), Estradiol (therapeutic use), Female, Macaca fascicularis, Microinjections, Ovariectomy, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (diagnostic imaging), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (metabolism), Postmenopause (drug effects), Postmenopause (metabolism), Radionuclide Imaging, Serotonin Plasma Membrane Transport Proteins (metabolism), Substantia Nigra (drug effects), Tritium.
- MESH :
- chemical , administration & dosage : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinsonian Disorders.
- diagnostic imaging : Brain, Parkinsonian Disorders.
- drug effects : Brain, Postmenopause, Substantia Nigra.
- drug therapy : Parkinsonian Disorders.
- metabolism : Brain, Parkinsonian Disorders, Postmenopause, Serotonin Plasma Membrane Transport Proteins.
- chemical , pharmacology : Estradiol.
- chemical , therapeutic use : Estradiol.
- Animals, Citalopram, Female, Macaca fascicularis, Microinjections, Ovariectomy, Radionuclide Imaging, Tritium.
Abstract
This study evaluated the effect of a one month 17β-estradiol treatment on brain serotonin (5-HT) reuptake transporter (SERT) in long-term ovariectomized (OVX) female monkeys (Macaca fascicularis) bearing a unilateral lesion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injected directly into the left substantia nigra modeling Parkinson disease (PD). Ovariectomy and MPTP lesion were performed four years before the estrogen treatment to model postmenopausal PD patients. SERT was measured by autoradiography using the radioligand [(3)H]Citalopram. Specific binding to SERT decreased in anterior cerebral cortex, nucleus accumbens, caudate nucleus and putamen on the lesioned side of 17β-estradiol and vehicle-treated monkeys compared to the intact side. In caudate nucleus and putamen the lesioned-induced decrease of [(3)H]Citalopram specific binding was more extensive in anterior and middle than posterior parts. [(3)H]Citalopram specific binding was increased in the cortex anterior cingulate gyrus of monkeys treated with 17β-estradiol in both brain hemispheres and was unchanged in the other brain regions investigated including the raphe nucleus. Positive correlations between [(3)H]Citalopram specific binding and 5-HT as well as 5-HIAA concentrations (reported previously) were obtained in the caudate nucleus and putamen and a negative correlation between SERT binding and 5-HIAA/5-HT concentration ratio suggesting MPTP lesion-induced 5-HT neuronal loss and lower 5-HT neurotransmission controlling and decreasing SERT for homeostasis. 17β-estradiol treatment initiated four years after ovariectomy of monkeys modeling hormonal conditions of post-menopause shows that SERT still displays some responsiveness to estrogens as observed in the anterior cingulate cortex. These results support a role of estrogens in 5-HT activity in PD.
DOI: 10.1016/j.pnpbp.2013.05.008
PubMed: 23719069
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000886
- to stream PubMed, to step Curation: 000886
- to stream PubMed, to step Checkpoint: 000886
Links to Exploration step
pubmed:23719069Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.</title><author><name sortKey="Sanchez, Maria Gabriela" sort="Sanchez, Maria Gabriela" uniqKey="Sanchez M" first="Maria Gabriela" last="Sánchez">Maria Gabriela Sánchez</name><affiliation wicri:level="1"><nlm:affiliation>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Quebec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23719069</idno><idno type="pmid">23719069</idno><idno type="doi">10.1016/j.pnpbp.2013.05.008</idno><idno type="wicri:Area/PubMed/Corpus">000886</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000886</idno><idno type="wicri:Area/PubMed/Curation">000886</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000886</idno><idno type="wicri:Area/PubMed/Checkpoint">000886</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000886</idno><idno type="wicri:Area/Ncbi/Merge">001464</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.</title><author><name sortKey="Sanchez, Maria Gabriela" sort="Sanchez, Maria Gabriela" uniqKey="Sanchez M" first="Maria Gabriela" last="Sánchez">Maria Gabriela Sánchez</name><affiliation wicri:level="1"><nlm:affiliation>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Quebec, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></analytic><series><title level="j">Progress in neuro-psychopharmacology & biological psychiatry</title><idno type="eISSN">1878-4216</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (administration & dosage)</term><term>Animals</term><term>Brain (diagnostic imaging)</term><term>Brain (drug effects)</term><term>Brain (metabolism)</term><term>Citalopram</term><term>Estradiol (pharmacology)</term><term>Estradiol (therapeutic use)</term><term>Female</term><term>Macaca fascicularis</term><term>Microinjections</term><term>Ovariectomy</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (diagnostic imaging)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (metabolism)</term><term>Postmenopause (drug effects)</term><term>Postmenopause (metabolism)</term><term>Radionuclide Imaging</term><term>Serotonin Plasma Membrane Transport Proteins (metabolism)</term><term>Substantia Nigra (drug effects)</term><term>Tritium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Postmenopause</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Parkinsonian Disorders</term><term>Postmenopause</term><term>Serotonin Plasma Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Estradiol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Estradiol</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Citalopram</term><term>Female</term><term>Macaca fascicularis</term><term>Microinjections</term><term>Ovariectomy</term><term>Radionuclide Imaging</term><term>Tritium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study evaluated the effect of a one month 17β-estradiol treatment on brain serotonin (5-HT) reuptake transporter (SERT) in long-term ovariectomized (OVX) female monkeys (Macaca fascicularis) bearing a unilateral lesion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injected directly into the left substantia nigra modeling Parkinson disease (PD). Ovariectomy and MPTP lesion were performed four years before the estrogen treatment to model postmenopausal PD patients. SERT was measured by autoradiography using the radioligand [(3)H]Citalopram. Specific binding to SERT decreased in anterior cerebral cortex, nucleus accumbens, caudate nucleus and putamen on the lesioned side of 17β-estradiol and vehicle-treated monkeys compared to the intact side. In caudate nucleus and putamen the lesioned-induced decrease of [(3)H]Citalopram specific binding was more extensive in anterior and middle than posterior parts. [(3)H]Citalopram specific binding was increased in the cortex anterior cingulate gyrus of monkeys treated with 17β-estradiol in both brain hemispheres and was unchanged in the other brain regions investigated including the raphe nucleus. Positive correlations between [(3)H]Citalopram specific binding and 5-HT as well as 5-HIAA concentrations (reported previously) were obtained in the caudate nucleus and putamen and a negative correlation between SERT binding and 5-HIAA/5-HT concentration ratio suggesting MPTP lesion-induced 5-HT neuronal loss and lower 5-HT neurotransmission controlling and decreasing SERT for homeostasis. 17β-estradiol treatment initiated four years after ovariectomy of monkeys modeling hormonal conditions of post-menopause shows that SERT still displays some responsiveness to estrogens as observed in the anterior cingulate cortex. These results support a role of estrogens in 5-HT activity in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23719069</PMID><DateCreated><Year>2013</Year><Month>07</Month><Day>23</Day></DateCreated><DateCompleted><Year>2014</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><PubDate><Year>2013</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology & biological psychiatry</Title><ISOAbbreviation>Prog. Neuropsychopharmacol. Biol. Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.</ArticleTitle><Pagination><MedlinePgn>170-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2013.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(13)00103-6</ELocationID><Abstract><AbstractText>This study evaluated the effect of a one month 17β-estradiol treatment on brain serotonin (5-HT) reuptake transporter (SERT) in long-term ovariectomized (OVX) female monkeys (Macaca fascicularis) bearing a unilateral lesion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injected directly into the left substantia nigra modeling Parkinson disease (PD). Ovariectomy and MPTP lesion were performed four years before the estrogen treatment to model postmenopausal PD patients. SERT was measured by autoradiography using the radioligand [(3)H]Citalopram. Specific binding to SERT decreased in anterior cerebral cortex, nucleus accumbens, caudate nucleus and putamen on the lesioned side of 17β-estradiol and vehicle-treated monkeys compared to the intact side. In caudate nucleus and putamen the lesioned-induced decrease of [(3)H]Citalopram specific binding was more extensive in anterior and middle than posterior parts. [(3)H]Citalopram specific binding was increased in the cortex anterior cingulate gyrus of monkeys treated with 17β-estradiol in both brain hemispheres and was unchanged in the other brain regions investigated including the raphe nucleus. Positive correlations between [(3)H]Citalopram specific binding and 5-HT as well as 5-HIAA concentrations (reported previously) were obtained in the caudate nucleus and putamen and a negative correlation between SERT binding and 5-HIAA/5-HT concentration ratio suggesting MPTP lesion-induced 5-HT neuronal loss and lower 5-HT neurotransmission controlling and decreasing SERT for homeostasis. 17β-estradiol treatment initiated four years after ovariectomy of monkeys modeling hormonal conditions of post-menopause shows that SERT still displays some responsiveness to estrogens as observed in the anterior cingulate cortex. These results support a role of estrogens in 5-HT activity in PD.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sánchez</LastName><ForeName>Maria Gabriela</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morissette</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Thérèse</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008845" MajorTopicYN="N">Microinjections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010052" MajorTopicYN="N">Ovariectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</Keyword><Keyword MajorTopicYN="N">5-HT</Keyword><Keyword MajorTopicYN="N">Brain</Keyword><Keyword MajorTopicYN="N">DA</Keyword><Keyword MajorTopicYN="N">Estradiol</Keyword><Keyword MajorTopicYN="N">MPTP</Keyword><Keyword MajorTopicYN="N">Monkey</Keyword><Keyword MajorTopicYN="N">OVX</Keyword><Keyword MajorTopicYN="N">PD</Keyword><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">SERT</Keyword><Keyword MajorTopicYN="N">Serotonin reuptake transporter</Keyword><Keyword MajorTopicYN="N">dopamine</Keyword><Keyword MajorTopicYN="N">ovariectomized</Keyword><Keyword MajorTopicYN="N">serotonin</Keyword><Keyword MajorTopicYN="N">serotonin reuptake transporter</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23719069</ArticleId><ArticleId IdType="pii">S0278-5846(13)00103-6</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2013.05.008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></noCountry><country name="Canada"><noRegion><name sortKey="Sanchez, Maria Gabriela" sort="Sanchez, Maria Gabriela" uniqKey="Sanchez M" first="Maria Gabriela" last="Sánchez">Maria Gabriela Sánchez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001464 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001464 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:23719069
|texte= Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:23719069" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |